← 홈

Antibody

163개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 163개
AntibodystaleNantes University HospitalPreclinical

CEEP-RITUXIMAB (CEEP-RITUXIMAB)

Lymphoma, Large-Cell, Diffuse · Lymphoma, Large-Cell, Diffuse

#LymphomaLarge-CellDiffuse#Antibody#Preclinical#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleWeill Medical College of Cornel…Phase 1

CHOP and alemtuzumab (CHOP and alemtuzumab)

T-Cell Lymphoma; Lymphoma, Non-Hodgkin's · T-Cell Lymphoma

#T-CellLymphoma#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleMedical College of WisconsinPhase 3

Cyclophosphamide and Rituximab (Cyclophosphamide and Rituximab)

Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma · Recurrent Grade 1 Follicular Lymphoma

#RecurrentGrade1FollicularLymphom#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleHeidelberg UniversityPhase 2

Cyclophosphamide, Pentostatin, Rituximab (Cyclophosphamide, Pentostatin, Rituximab)

Immunocytoma/Morbus Waldenström; B-Cell Non-Hodgkin's Lymphoma · Immunocytoma/Morbus Waldenström

#ImmunocytomaMorbusWaldenstrm#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleZeneus PharmaPhase 2

R-COMP (Cyclophosphamide, oncovin, myocet, prednisone & rituximab, Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP))

Aggressive Non-Hodgkin's Lymphoma in the Elderly. · Aggressive Non-Hodgkin's Lymphoma in the

#AggressiveNon-HodgkinsLymphomain#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystalePeking UniversityPhase 2

Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (Dexamethasone, azacytidine, Pegaspargase, Tislelizumab)

NK/T Cell Lymphoma · NK/T Cell Lymphoma

#NKTCellLymphoma#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleUniversity of Illinois at Chica…Phase 3

Elra (Elranatamab, Elranatamab (Elra))

Plasmablastic Lymphoma; Hiv · Plasmablastic Lymphoma

#PlasmablasticLymphoma#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab (Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab)

Primary Mediastinal Large B Cell Lymphoma · Primary Mediastinal Large B Cell Lymphom

#PrimaryMediastinalLargeBCellLymp#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe Lymphoma Academic Research …Phase 1

Everolimus and rituximab (Everolimus and rituximab)

Non-Hodgkin's Lymphomas · Non-Hodgkin's Lymphomas

#Non-HodgkinsLymphomas#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix)

Primary Central Nervous System Lymphoma · Primary Central Nervous System Lymphoma

#PrimaryCentralNervousSystemLymph#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGlenmark Specialty S.A.Phase 1

atezolizumab (Tecentriq, GRC 54276 + Atezolizumab)

Advanced Solid Tumor; Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleGlenmark Specialty S.A.Phase 1

pembrolizumab (Keytruda, GRC 54276 + Pembrolizumab)

Advanced Solid Tumor; Lymphoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 1

HDMP + rituximab as a means of debulking prior to initiating venetoclax. (HDMP + rituximab as a means of debulking prior to initiating venetoclax.)

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia or Small Ly

#ChronicLymphocyticLeukemiaorSmal#Antibody#Phase1#항체#면역항체+2
효능 ORR 1%임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

High-dose Epirubicin Combined with CVP ± Rituximab (High-dose Epirubicin Combined with CVP ± Rituximab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Lenalidomide and rituximab (R2, Lenalidomide and rituximab, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.)

Follicular Lymphoma (FL) · Follicular Lymphoma (FL)

#FollicularLymphomaFL#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleGeorgetown UniversityPhase 1

Lenalidomide, Ibrutinib, Rituximab (Lenalidomide, Ibrutinib, Rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleADC TherapeuticsPhase 1

durvalumab (Imfinzi, Loncastuximab Tesirine and Durvalumab)

Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED

4 / 9 페이지

← 이전다음 →